載入...

Bortezomib at therapeutic doses poorly passes the blood–brain barrier and does not impair cognition

The 26S proteasome inhibitor bortezomib is currently used to treat multiple myeloma but also is effective in the treatment of antibody-mediated autoimmune disorders. One clinical concern is bortezomib’s toxicity towards the (central) nervous system. We used standardized neuropsychological testing to...

全面介紹

Na minha lista:
書目詳細資料
發表在:Brain Commun
Main Authors: Huehnchen, Petra, Springer, Andreas, Kern, Johannes, Kopp, Ute, Kohler, Siegfried, Alexander, Tobias, Hiepe, Falk, Meisel, Andreas, Boehmerle, Wolfgang, Endres, Matthias
格式: Artigo
語言:Inglês
出版: Oxford University Press 2020
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7425526/
https://ncbi.nlm.nih.gov/pubmed/32954282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/braincomms/fcaa021
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!